Search

Your search keyword '"Günthard, Huldrych"' showing total 2,258 results

Search Constraints

Start Over You searched for: Author "Günthard, Huldrych" Remove constraint Author: "Günthard, Huldrych"
2,258 results on '"Günthard, Huldrych"'

Search Results

1. Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

3. 2022 update of the drug resistance mutations in HIV-1.

4. Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV

5. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

7. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

8. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

9. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

10. Assessing immunogenicity barriers of the HIV-1 envelope trimer

11. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

12. Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1

13. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

14. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

15. Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years

16. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

17. 2019 update of the drug resistance mutations in HIV-1.

18. Reply to Ambrosioni et al.

19. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel

20. Canakinumab in patients with COVID-19 and type 2 diabetes – A multicentre, randomised, double-blind, placebo-controlled trial

21. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

22. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

23. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

24. Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.

25. Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.

26. Trends in Mortality in People With HIV From 1999 through 2020: A Multicohort Collaboration.

27. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study.

28. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

29. Impact of hormonal therapy on HIV‐1 immune markers in cis women and gender minorities.

31. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

32. Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

33. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

35. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV

36. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

37. Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection

38. Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV

39. Genetic diversity from proviral DNA as a proxy for time since HIV-1 infection

40. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection

41. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

42. Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL’HIV open-label, factorial randomised controlled trial

43. Cohort Profile: The Zurich Primary HIV Infection Study

44. Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study

45. Phenotypic and genotypic characterization of Neisseria gonorrhoeae isolates among individuals at high risk for sexually transmitted diseases in Zurich, Switzerland

46. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy

47. Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy

48. Decreased Physical Activity and Prolonged Sitting Time Are Associated With Liver Steatosis in People With HIV

49. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland

50. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

Catalog

Books, media, physical & digital resources